Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Shares Outstanding (Weighted Average): 2018-2025

Historic Shares Outstanding (Weighted Average) for Autolus Therapeutics (AUTL) over the last 8 years, with Sep 2025 value amounting to $266.1 million.

  • Autolus Therapeutics' Shares Outstanding (Weighted Average) rose 0.02% to $266.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.1 million, marking a year-over-year increase of 0.02%. This contributed to the annual value of $266.1 million for FY2024, which is 0.07% up from last year.
  • Per Autolus Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $266.1 million for Q3 2025, which was down 0.00% from $266.1 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $266.1 million in Q2 2025 and a low of $70.5 million during Q1 2021.
  • Over the past 3 years, Autolus Therapeutics' median Shares Outstanding (Weighted Average) value was $266.0 million (recorded in 2024), while the average stood at $240.8 million.
  • Data for Autolus Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 191.80% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Shares Outstanding (Weighted Average) stood at $72.9 million in 2021, then grew by 24.98% to $91.1 million in 2022, then surged by 191.80% to $265.9 million in 2023, then rose by 0.07% to $266.1 million in 2024, then climbed by 0.02% to $266.1 million in 2025.
  • Its last three reported values are $266.1 million in Q3 2025, $266.1 million for Q2 2025, and $266.1 million during Q1 2025.